Peptide Schedule
Syn-Ake3 residues (approx.)APKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Syn-Ake Dosage Calculator
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate, Tripeptide-3) is a synthetic tripeptide engineered to mimic the paralytic action of Waglerin-1, a 22-amino-acid peptide found in the venom of the Temple Pit Viper (Tropidolaemus wagleri).
2mcg · Daily
Summary: Add 0mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 2mcg dose. This vial will last 0 doses.
Cycle Planner
Syn-Ake Pharmacokinetics
Syn-Ake Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | Daily |
| Moderate | 4mg | 2x Daily |
| Aggressive | 6mg | 2x Daily |
Note: Topical neuromuscular anti-aging peptide also known as Tripeptide-3 or Dipeptide Diaminobutyroyl Benzylamide Diacetate (CAS 823202-99-9). Synthetic biomimetic of Waglerin-1 from the Temple Pit Viper (Tropidolaemus wagleri). Molecular weight 495.58 Da. Formula: C23H37N5O7. Sequence: beta-Ala-Pro-Dab-NH-benzyl (diacetate salt). Developed by Pentapharm Ltd (now DSM-Firmenich). Standard concentration in commercial formulations is 4% in topical serums and creams. Dosing tiers above reflect approximate mg of active peptide per topical application. Apply to clean, dry skin on expression-line-prone areas (forehead, periorbital, perioral).
About Syn-Ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate, Tripeptide-3) is a synthetic tripeptide engineered to mimic the paralytic action of Waglerin-1, a 22-amino-acid peptide found in the venom of the Temple Pit Viper (Tropidolaemus wagleri). The peptide functions as a competitive antagonist of the muscular nicotinic acetylcholine receptor (mnAChR), specifically binding to the epsilon subunit to block acetylcholine from activating the receptor. This prevents sodium ion channel opening, blocks nerve excitation transmission, and induces localized muscle relaxation — a mechanism analogous to botulinum toxin but achieved through topical application rather than injection. In vitro experiments using cultured muscle cells demonstrated that a 0.025% concentration of Syn-Ake reduced the muscle cell contraction rate by 36% within one minute and by 82% after two hours, with the effect being fast-acting, long-lasting, and fully reversible. In a manufacturer-sponsored clinical study of 45 subjects applying a 4% Syn-Ake cream to the forehead, wrinkle depth was reduced by up to 52% after 28 days of daily use. An independent three-month, single-center clinical study (Trookman et al. 2009) evaluated a formulation containing a Waglerin-1-mimicking peptide in 37 women aged 33-45 with periocular and perioral wrinkles, demonstrating statistically significant wrinkle reduction at all timepoints (p <= 0.0003), with 83% of subjects rating satisfaction as excellent or good. The peptide's low molecular weight (495.58 Da, below the 500 Da skin penetration threshold) enables passage through the stratum corneum without requiring lipid conjugation. In silico and in vitro analyses (Gok et al. 2024) confirmed additional antioxidant properties through DPPH radical scavenging, strong binding affinity to SIRT1 (-9.32 kcal/mol) and MMP-13 receptors, and a favorable safety profile based on cytotoxicity and genotoxicity assessments. A 2020 review in Frontiers in Chemistry noted that while manufacturer data is compelling, independent peer-reviewed clinical studies on Tripeptide-3 specifically remain limited. The Cosmetic Ingredient Review process has not flagged safety concerns, and the EWG Skin Deep database rates the ingredient as low risk across all toxicity categories. Syn-Ake is not FDA-approved for any medical indication and is classified as a cosmeceutical research ingredient with strong in vitro evidence and moderate clinical evidence.